Is This an Anchor for Eli Lilly Investors?

Eli Lilly , like many of its peers in the pharma industry, continues to battle the effects of the patent cliff. Two of its three top-selling products will lose exclusivity this year, but there is one jewel in its crown that investors don't need to worry about. In this video, health care analyst Max Macaluso dives into this drug's clinical use and growth.

Can Lilly defeat the patent cliff?
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.


The article Is This an Anchor for Eli Lilly Investors? originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Income Investing

Grow your nest-egg.

View Course »

Goal Setting

Want to succeed? Then you need goals!

View Course »

Add a Comment

*0 / 3000 Character Maximum